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ABSTRACT: The ﬁeld of regenerative medicine has been gaining momentum steadily
over the past few years. The emphasis in regenerative medicine is to use various in vitro and
in vivo approaches that leverage the intrinsic healing mechanisms of the body to treat
patients with disabling injuries and chronic diseases such as diabetes, osteoarthritis, and
degenerative disorders of the cardiovascular and central nervous system. Phage display has
been successfully employed to identify peptide ligands for a wide variety of targets, ranging
from relatively small molecules (enzymes, cell receptors) to inorganic, organic, and
biological (tissues) materials. Over the past two decades, phage display technology has
advanced tremendously and has become a powerful tool in the most varied ﬁelds of
research, including biotechnology, materials science, cell biology, pharmacology, and
diagnostics. The growing interest in and success of phage display libraries is largely due to
its incredible versatility and practical use. This review discusses the potential of phage
display technology in biomaterials engineering for applications in regenerative medicine.
Regenerative medicine (RM) is a growing ﬁeld of inter-disciplinary research and clinical practices that has the
potential of transforming the future of healthcare. It seeks to
repair or replace malfunctioning cells, tissues, or organs caused
by genetic disorders, chronic diseases, injuries, or aging.1
It employs a combination of in vitro/ex vivo and in vivo
approaches that may involve transplantation of stem/progenitor,
diﬀerentiated, or engineered cells, alone or incorporated in bio-
material scaﬀolds; tissue engineering; and delivery of therapeutic
agents (e.g., cytokines, genes, small molecules) for reprogram-
ming cell and tissue types or improving the function of the host
environment. All RM strategies leverage the stimulation of the
body’s endogenous processes to develop and repair. Accordingly,
stem cell research, gene therapy, biomaterials science, and
molecular imaging play a central role in RM.
Phage display is a potent, high-throughput technology used for
identifying peptide ligands for a given target. The technique
applies a library of phage particles displaying an ample variety of
peptides or proteins to identify those that bind to a certain target.
The utility of this technology derives from phage biology, as
phages can be genetically modiﬁed to express polypeptides on
their surface while the gene encoding the polypeptide, found
inside the viral particle, can be analyzed. Since its ﬁrst estab-
lishment by Smith in 1985,2 phage display has enabled the
selection of a vast quantity of diﬀerent peptides. Although mostly
used to discover peptide ligands for mapping protein−protein
interactions, and in the ﬁeld of antibody engineering, phage
display has evolved, now contributing to a variety of diﬀerent
areas of medicine and technology. Some of those areas that now
beneﬁt from the system are molecular and imaging diagnosis,3
peptide drug discovery,4 targeted drug and gene delivery,5 vac-
cine development,6 identiﬁcation of new receptors and ligands,6
and nanomaterials.7,8 Several excellent reviews, covering diﬀer-
ent aspects of phages, including phage biology9 and the appli-
cation of phage display in diﬀerent areas,6,10−12 have been
published.
Cell transplantation often requires prior expansion of the cells
in vitro to obtain large numbers of functional cells for clinical
applications. Thus, in vitro expansion is a critical step in cell-based
therapies and typically involves the culture of cells on substrates
coated with extracellular matrix (ECM) proteins. However, the
batch-to-batch variability of ECM proteins presents limitations
for both basic research and clinical applications of stem cells.
Phage display technology provides a nonexpensive tool for the
rapid and eﬃcient screening of peptide ligands on cells or tissues,
discriminating between subtle diﬀerences in cell surface pheno-
types and between normal or diseased tissues. These peptide
motifs can be incorporated into biomaterials to guide stem cell
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proliferation and diﬀerentiation in vitro for subsequent trans-
plantation, or to recruit local stem cells in vivo for stimulating
tissue regeneration. When phage-derived peptides targeting
speciﬁc cells or tissues are used, rather than the nonspeciﬁc
peptide motifs routinely used in RM approaches, more con-
trollable and eﬀective regenerative therapies can be developed
and tailored to individual patients, leading toward personalized
medicine. In addition, phage display can provide novel peptides
to investigate peptide−protein interactions that underlie disease
mechanisms, which can be further used for designing potential
therapeutic agents. Thus, peptide phage display is also a valuable
tool in RM, and several therapeutic products generated by this
technology are now commercially available,4 demonstrating its
clinical potential. This review aims to recount the applications of
phage display in biomaterials engineering and RM, highlighting
the future of phage display in these ﬁelds.
Phage Display Screening - Biopanning. The most
common screening method to identify peptide ligands for a
given target by phage display (aﬃnity selection) is known as
biopanning. This procedure employs a phage display library that
consist of a pool of individual clones (∼109) bearing a diﬀerent
foreign DNA insert in the phage genome and presenting a dif-
ferent peptide on its surface. The external gene sequence is
merged between genes encoding a signal peptide and a part of
the capsid protein, which ensures that the a foreign peptide is
expressed fused to the coat proteins. Molecules displayed on
phage libraries are not restricted to peptides and antibodies.
Random protein fragments, gene-fragment- or cDNA-encoded
proteins, and mRNA phage display libraries have also been
created,13,14 broadening the practical applications of the tech-
nology and demonstrating its versatility.
Typically, the process starts with library exposure to the target
of interest to allow binding to the target under suitable con-
ditions. The loosened phages are eliminated by washing, and the
remaining bound phages are then eluted for subsequent bacterial
infection and ampliﬁcation. Viral multiplication occurs within the
host cells, and thousands of newly formed phage particles are
generated for additional selection rounds (usually 2−5 rounds).
After multiple panning rounds, enrichment of the target-binding
phage is analyzed by phage titering and/or immunological assays.
When suﬃcient enrichment is achieved, single phages are
separated and sequenced to identify predominant binding motifs
(consensus sequence). Selective clones may be obtained by
examining the diﬀerences between unselected and selected
libraries using DNA sequencing.15,16
Selection of ligands able to distinguish particular features in
biological scenarios (cells and tissues) with good speciﬁcity and
aﬃnity is required for reliable diagnosis and eﬀective regenerative
therapies. Hence, potential targets in RM are signaling proteins
(e.g., growth factors), cells, and tissues. These targets, however,
have many potential binding sites, and nonspeciﬁc binding to
abundant molecules (e.g., albumin) is also believed to aﬀect the
outcome of the panning experiments. Hamilton and co-workers17
described the application of phage display to select peptides
that bind to bone morphogenetic protein 2 (BMP-2), which
is implicated in osteoblast diﬀerentiation and stimulates bone
formation. Using a recombinant form of human BMP-2
(rhBMP-2), they ﬁrst biotinylated the protein for immobilization
on streptavidin (SA)-coated microtiter plates. Biopanning was
performed according to conventional protocols. After three
cycles of screening, the populations of enriched phages were
ampliﬁed in bacteria, and the binding to BMP-2 was detected by
an enzyme linked immunosorbent assay (ELISA).
Many studies do not take into account the fact that the high
density of receptors at the selection surface does not reproduce
the density of receptors present on the native cell membrane.
Thus, the binding aﬃnity of the isolated peptide might be lower
than the one observed when displayed on the phage. For
example, Bastings et al.18 demonstrated, using SA as a model
multivalent receptor, that receptor density and ligand valency
are important parameters associated with binding strength.
They showed that phage aﬃnity for SA-coated surfaces declines
signiﬁcantly into the nanomolar scale when the surface density of
SA is reduced. By displaying the peptide ligand in a multivalent
arrangement (e.g., dimer, tetramer, or pentameric peptide
wedge), they were able to increase (104-fold) the binding aﬃn-
ity as compared to the monovalent peptide. This study suggests
that for eﬀective targeting strategies, both the ligand presentation
and the density of the corresponding receptor are fundamental
aspects to consider. The ligand selection should be conducted on
surfaces with physiologically representative receptor densities,
and the peptides identiﬁed by phage display should be displayed
in an appropriate form (e.g., dendrimer) when engineering
biomaterials aiming for successful targeting. In addition, the cell
surface contains proteins that can cluster or multimerize, and
some of these organization patterns can be disturbed upon
preparation of membrane proteins for selective screening.
Indeed, the hydrophobic segments of membrane proteins direct
them into a lipophilic environment, with such proteins naturally
aggregating after separation from the membrane. Recombinant
forms of these proteins have been widely used, but recombinant
receptors are not always available. Hajduczki et al.19 proposed
a new approach for the solubilization and presentation of
membrane proteins, by proposing a diﬀerent strategy for phage
display selection. They prepared a phage library displaying
caveolin-1 (monotopic membrane protein associated with
detergent-insoluble rafts) variants generated by site-directed
mutagenesis and used an antiselection process, consisting of
binding to a hydrophobic resin, to eliminate aggregation-prone
hydrophobic variants. The less hydrophobic variants were
subsequently recovered and used in positive selection to isolate
variants binding to the gp41 ectodomain (a known caveolin
function). This additional positive panning ensured that the
obtained variants were correctly folded. Thus, phage display
screening on whole cells oﬀers more chances to obtain peptides
that bind to transmembrane proteins in their natural confor-
mation. Panning on living cells can be done either onmonolayers
of attached cells or on cells in suspension. In these cases, the pool
of target-binding phages needs to be diverse, but it can be
reduced by performing a negative screening (preclearing) on
“control” cells20 or a funnel screening protocol. Kiessling’s
group21 used a screening approach based on the biopanning and
rapid analysis for selective interactive ligands (BRASIL) method,
previously developed by Giordano and co-workers,20 to isolate
peptides binding to the surface of live stem cells. BRASIL is more
speciﬁc (panning of cells in suspension) and faster than con-
ventional methods that depend on washing or limiting dilution.
Because living stem cells present many diﬀerent receptors on
their surfaces, and no appropriate “control cells” were available
for a negative selection step, they further optimized the screening
to narrow down the pool of cell-binding peptides. They incu-
bated the cells (human embryonal carcinoma cell line) with a
mixture (1:1) of a peptide-bearing (library) and peptide-free
(wild type) phage and monitored phage titer at each panning and
washing step. The phage members that remained bound to cells
after all washing stages were then subjected to an additional cycle
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of incubation and washing, resulting in 50-fold enrichment of the
peptide-containing phage. However, many nonspeciﬁc phages
remained in the pool. Therefore, to select the cell-binding phage,
they employed another screening step using ELISA. Seven cell-
binding phage clones were isolated from the 370 clones tested.
Since the human body is made of around 1014 cells with
distinct types and the surface changes with the state of the cell,
the problem gains further complexity in vivo. Although most
biopanning experiments are conducted in vitro, it is recognized
that the in vivo conditions greatly inﬂuence the expression of cell
surface molecules and that the phenotype of certain cells changes
when they are cultured in vitro. Thus, the application of phage
display selection in vivo circumvents these challenges and allows
the identiﬁcation of ligands capable of homing to speciﬁc tissues
or organs.6,22−25 In order to achieve this process, phage libraries
are injected intravenously into animals and allowed to circulate
for a certain time. While nonspeciﬁc phages tend to be found
throughout the whole organism, phages with selective binding
will concentrate in certain tissues or organs. The bound phages
are recovered and ampliﬁed, and their DNA is sequenced.
Pasqualini and Ruoslahti24 were the ﬁrst to report this approach,
isolating peptides that home to renal and cerebral vascular
endothelium in vivo. In vivo panning has also been applied to
identify peptide ligands with potential applications in RM. For
example, Nowakowski et al.26 were the ﬁrst to conduct a phage
display experiment involving the bone marrow and stem cells.
They injected the phage display library into the tail vein of mice
and, 10 min after injection, isolated the bone marrow to elute
phages bound to bone marrow cells. The eluted phages were
puriﬁed, ampliﬁed, and then reinjected. Five rounds of screening
resulted in the identiﬁcation of a peptide that preferentially
homes to bone marrow, also binding to resident hematopoietic
stem cells. The receptor of this peptide may be involved in bone
marrow engraftment by recruiting hematopoietic stem cells.
One of the most laborious and costly steps (rate-limiting) in
phage display screening is the DNA sequencing of the encoded
displayed peptides. Next generation sequencing (NGS), such as
Illumina deep sequencing technology, permits a high-throughput
and cost-competitive phage display selection because it can
characterize over 107 reads in a single run, providing more
complete coverage of the libraries.27 This is particularly useful for
panning on RM targets such as cells, which present hundreds of
diﬀerent receptors. For example, Hoen and colleagues28 applied
NGS to analyze the phage library at diﬀerent stages of the
selection process when panning on KS483 osteoblast cells,
ﬁnding positive hits after one round of selection. Since its ﬁrst
application, NGS has been applied to enhance phage display
protocols,28−31 allowing the isolation of phage binders after
the ﬁrst biopanning round, and the selection of less frequent
but more speciﬁc peptides. As an example, a new method for
selection against targets located on the cell surface, which are less
abundant and cannot be puriﬁed, was implemented by the Lerner
lab.32 This method allows for the identiﬁcation of ligands for less-
ﬁt molecules with lower aﬃnity. Having ligands with lower
aﬃnity can be useful for neutralizing the function/activity of the
target through binding to diﬀerent regions.
In the following sections, we describe applications of phage-
derived peptides in the functionalization of novel biomaterials
with potential implications in RM strategies.
Figure 1. The use of phage display (center: M13 phage displaying a random peptide library on coat-protein 3) in biomaterials engineering and their
applications in in vitro (a, b) and in vivo (c, d) RM approaches. (a) Functionalized synthetic substrates (2D surfaces) for stem cell expansion. (b)
Functionalized hydrogels (3D environments) for recreating/manipulating stem cell niches. (c) Functionalized injectable biomaterials for sequestering
GFs to promote endogenous tissue repair. (d) Functionalized nanocarriers for cell reprogramming (target delivery of genetic material to speciﬁc cells).
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■ APPLICATIONS OF PHAGE DISPLAY IN
BIOMATERIALS ENGINEERING FOR REGENERATIVE
MEDICINE
The advances in phage display have greatly expanded the
applications of the technology, creating new opportunities in
biomaterials engineering and RM. Figure 1 shows examples of
in vitro and in vivo RM strategies using diﬀerent biomaterial
systems functionalized with peptides identiﬁed by phage display.
Phage-derived peptides, able to bind speciﬁcally to receptors on
the surface of stem cells, can be used to functionalize synthetic
scaﬀolds (2D surfaces and 3D hydrogels) for promoting stem cell
expansion (Figure 1a) or diﬀerentiation (Figure 1b) in vitro.
In vivo approaches include the incorporation of peptide ligands
identiﬁed by phage display into injectable biomaterials
(e.g., nanoﬁbers), which can bind to growth factors (GFs) and
promote endogenous tissue repair (Figure 1c), or into
nanobiomaterials (e.g., liposomes, dendrimers), which can bind
to receptors on the cell surface and deliver genetic material to
target cells (gene therapy, Figure 1d).
Diﬀerent databases (PepBank, Tree of Medicine, BDB)
collating peptide sequences identiﬁed by phage display can be
accessed free of charge, greatly contributing to data mining in this
area. Currently, the biopanning data bank (BDB, at http://
immunet.cn/bdb/) formerly known as MimoDB33,34 contains
26 813 peptide sequences, showing that the use of phage display
has exploded over recent decades. However, many of the dis-
covered sequences have not been further analyzed and validated
in vitro or in vivo to assess speciﬁcity, selectivity, and stability, nor
have they had their structure optimized to be clinically useful.
To facilitate the search of sequences with utility for RM appli-
cations, we have compiled in Table 1 a selected list of peptide
sequences that bind to RM targets (i.e., ECM components of
tissues, GFs, surface of stem and diﬀerentiated cells). These
peptide ligands can be used to speciﬁcally localize imaging probes
or drugs to damaged tissues for diagnostic (immunohistochem-
istry, magnetic resonance imaging, positron emission tomog-
raphy) and therapeutic (treating diseases) purposes; to deliver
diﬀerent biologics (e.g., GFs, oligonucleotides) to selected cell
types for controlling their behavior (adhesion, survival, pro-
liferation, migration, diﬀerentiation, angiogenesis); or to recruit
local stem cells to sites of injury for stimulating tissue regen-
eration. The BiopanningDataSet ID was also included, when
available, to facilitate the search in BDB, as well as the equi-
librium dissociation constant (KD), which represents the binding
aﬃnity between the peptide ligand and the target, or the half
inhibitory concentration (IC50) from competition binding
assays. In addition, a follow-up was performed to identify trans-
formative publications that have identiﬁed breakthrough
sequences, inspired new experiments based on the original
sequence, and contributed to their application and clinical devel-
opment, with potential impact on RM. To discriminate such
contributions, quantitative data on the number of citations for
each publication were ﬁrst gathered, and from these, original
articles were selected (excluding reviews, editorials, book
chapters) to perform the analysis. While carrying out this
evaluation, we must bear in mind that, typically, there is a 1−3
year citation lag time for each article with impact, and certain
sequences have been only recently published. Table 1 also
summarizes the outcome of this analysis by identifying the
number of publications that describe subsequent use of the
original peptide sequence in diverse experimental studies,
including in vitro and in vivo testing/characterization, and
optimization/formulation toward their medical applica-
tion. More details on this analysis can be found in Table S1
(Supporting Information). Many of the listed sequences have not
resulted in any follow-up papers, mainly because they have been
only recently discovered. One exception is compstatin, a cyclic
tridecapeptide ﬁrst identiﬁed by Sahu35 from phage-display
libraries, which binds to complement component 3 (C3), a
protein of the immune system. An excellent review on the
“clinical trajectory” of compstatin was provided by Ricklin and
Lambris.36 This peptide has contributed signiﬁcantly to the
understanding of compstatin−C3 interactions and the gener-
ation of new therapeutics (complement inhibitors). Compstatin,
and in particular POT-4 (Table S1), which has been com-
mercialized by Potentia Pharmaceuticals, Inc., has entered phase
I clinical trials for the treatment of age-related macular
degeneration and can be used for biomaterial functionalization
to inhibit biomaterial-induced complement activation.37
In some cases, more than one sequence is identiﬁed for the
same target. For example, when screening hydroxyapatite (HAP)
materials, diﬀerent powder particles, of various sizes and
morphologies, used for the selection may explain the observed
diﬀerences. Ideally, the selection should be performed using a
material with speciﬁc morphology, crystallography, and stereo-
chemistry. As described previously, several phage clones are
selected in a ﬁrst screening, and the relative aﬃnity tends to
increase with an increasing number of panning cycles. After this
ﬁrst screening, isolated clones are analyzed by ELISA, for
example, for cross reactivity and binding ability. Sequences with
varied aﬃnities (high, intermediate, or low binding constants)
can be obtained, thus allowing the engineering of binding aﬃnity
and speciﬁcity. Furthermore, by comparing the sequences
obtained by phage display with the ones derived from natural
proteins known to bind to the same targets, diﬀerences in the
amino acid composition and sequence are also observed. For
example, Mummert et al.42 found a 12-mer peptide that binds to
hyaluronan (HA, Table 1) using phage display. This peptide
sequence does not show signiﬁcant (>25%) similarity with the
HA-binding motifs found in hyaladherins (CD44, RHAMM, or
link protein)69 nor does it show a consensus domain, known to
be identical among these three HA-binding proteins.69 None-
theless, the authors showed that the phage-identiﬁed peptide
speciﬁcally binds to HA free in solution or bound to a substrate,
and also to HA expressed on the cell surface, and that prevented
the binding of HA to leukocytes and their attachment to HA
coated surfaces. In addition, this sequence has been validated in
numerous subsequent studies (Table S1).
Biomaterials Functionalized with Peptide Ligands
Identiﬁed by Phage Display as in Vitro Cell Culture
Models. The isolation and culture of human stem cells in vitro
have largely contributed to important advances in fundamental
cell biology and cell therapies, by understanding the molecular
mechanisms involved in the processes by which stem cells
undergo self-renewal or diﬀerentiation.70 Recent discoveries
have shown novel mechanisms by which stem cell fate is
regulated,71−73 but continued research in the molecular biology
of stem cells will boost their application in RM. A challenge in
cell-based therapies is to ﬁnd adequate sources of stem cells and
the need for maintaining them undiﬀerentiated during in vitro
expansion. Thus, there is an urgent need to develop precise and
reproducible culturing systems able to control the behavior
of human stem cells in vitro. In addition, for cell therapies in
humans, an essential requirement is to avoid the exposure of stem
cells to animal-derived components during culture. Advances in
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biomaterials engineering have enabled the development of
in vitro culture platforms for cell expansion, and also for the
diﬀerentiation of stem cells into speciﬁc lineages. In vivo, cells
receive signals from the ECM and other cells through specialized
transmembrane proteins that bind to components of the ECM
and receptors of neighboring cells. One potential approach to
mimic these interactions and guide cell growth or diﬀerentiation
in vitro is the use of biomaterials based on peptide sequences that
bind to those cell receptors. Phage display has been applied to
probe the surface of diﬀerent stem cells, including adipose
progenitor cells,49,50 bone marrow-derived mesenchymal stem
cells (MSCs),26,51−53,74 and embryonic stem cells (ESCs)21,54−56
(Table 1). The latter are of special interest, considering their
diﬀerentiation pluripotency. Peptide ligands for stem cell recep-
tors can then be broadly used in cell culture and diﬀerentiation
(immobilized on 2D surfaces or 3D hydrogels), namely, as
probes for detection of speciﬁc stem cell populations during
isolation procedures or to ascertain the role of proteins for stem
cell diﬀerentiation.
2D Substrates for the Controlled Expansion (and/or
Diﬀerentiation) of (Stem) Cells. Kiessling and collaborators21
used a peptide sequence identiﬁed by phage display (bind-
ing receptors on human embryonal carcinoma, Table 1) for
culturing ESCs. Using self-assembled monolayers (SAMs) for
displaying bound peptide ligands on a synthetic surface (Figure 2a1),
they showed that these chemically deﬁned functional substrates
supported the undiﬀerentiated proliferation of pluripotent cells
(Figure 2a2). These cells are capable of replicating indeﬁnitely
and generate all human cell types, oﬀering a useful resource
for both research and RM. Thus, a surface with a well-deﬁned
composition could eliminate the problem associated with the use
of animal-derived proteins, which suﬀer from batch-to-batch
variability, and increase the predictability of culturing cells
in vitro.
Similarly, MSCs cultured on peptide SAMs containing BMHP1
(Table 1, Figure 2b1) in maintenance medium (DMEM) or
osteogenic diﬀerentiation medium (ODM) were able to pro-
duce higher amounts of calcium than when cultured on bare
substrates (Figure 2b2,b3), demonstrating that BMHP1 can
enhance cell mineralization. It was also shown that the amount
of calcium deposition was dependent on the peptide density
(Figure 2b3).
These studies showed the utility of the identiﬁed peptides for
elucidating cell−matrix interactions in 2D. This information
could be translated for the functionalization of 3D biomaterials to
control cell behavior.
Figure 2. 2D biomaterials (surfaces) functionalized with peptide sequences identiﬁed by phage display for in vitro cell culture (proliferation and
diﬀerentiation). (a) Synthetic surfaces of SAMs displaying phage-derived peptides that bind to the surface of human ESCs support their undiﬀerentiated
growth. (a1) SAMs composed of perﬂuorinated alkanethiols (ATs) containing diﬀerent ratios of peptide-AT and glucamine-AT (nonadherent for cells)
to obtain surface arrays of peptides with diﬀerent densities. (a2) Human ESCs (hESCs) proliferating on peptide-AT SAMs maintain expression of
markers of pluripotency (Oct4 and SSEA4). Adapted with permission from ref 21. Copyright 2010 American Chemical Society. (b) BMHP1
immobilized on 2D surfaces induce the osteogenic diﬀerentiation of MSCs. (b1) Linear and cyclic BMHP1 (cBMHP1) were conjugated to maleimide-
functionalized quartz substrates via a cysteine residue inserted in the N-terminus. (b2) Low-magniﬁcation (200×) inverted microscopy images of
Alizarin Red S (forms a bright red complex with calcium) staining onMSCs cultured on bare and peptide-functionalized surfaces in DMEM (top panel)
and ODM (bottom panel) for 7 days (insets show macroscopic images). (b3) Colorimetric quantiﬁcation of calcium deposition by cells cultured in
DMEM (left) and ODM (right). Adapted with permission from ref 75. Copyright 2015 The Royal Society of Chemistry.
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Growth factors (GFs) are involved in numerous cellular
processes, such as cell growth, diﬀerentiation, and migration.
TGF-β is able to both positively and negatively aﬀect inﬂam-
mation and wound healing. Thus, several studies have been
performed toward the identiﬁcation of peptide ligands with
selectivity and aﬃnity to this GF and its receptors, aiming to
understand their interactions and thus develop new strategies to
tune their signaling capacity.
The regenerative potential of surfaces functionalized with
TGF-β1-binding peptide (Table 1) through azide-terminated
SAMs and microcontact printing, and preloaded with TGF-β1,
was evaluated by culturing human articular chondrocytes (hACs)
on the material.76 After 7 days of culture, more cells were
observed on the peptide-functionalized surfaces than on the bare
azide SAMs. Chondrocytes cultured in the absence of TGF-β1
were found to be more extended, resembling the typical mor-
phology of ﬁbroblasts, while those cultured in the presence of
TGF-β1 exhibited a round polygonal shape, representative of
chondrocyte phenotype. In addition, glycosaminoglycan (GAG)
analysis revealed higher levels of GAGs in lysates of hACs
cultured on peptide-functionalized surfaces with bound TGF-β1
compared to hACs cultured on glass and with the GF free in the
medium, and for cultures on peptide-functionalized surfaces
without TGF-β1.
Using phage display, two peptides that bind speciﬁcally to
the TGF-β receptor II (TβRII; Table 1) have been identiﬁed.66
These peptides can mimic or block distinct functions of
TGF-βI and can be used to regulate these diﬀerent functions,
separately or in concert, which are important for vascular
therapy. The group of Kiessling also used phage display to
identify peptide ligands speciﬁc for TGF-β receptors I and II65
(Table 1). They showed that the identiﬁed peptides bind to the
receptors in a region diﬀerent from the binding site used by
TGF-β, thus not interfering with TGF-β signaling. Therefore,
these ligands can be applied as tools to examine the diverse
cellular functions of TGF-β, as well as to promote the
identiﬁcation of potential therapeutics. Indeed, in later work,
Kiessling and co-workers employed SAMs to present the
Figure 3. 3D biomaterials (hydrogels) functionalized with peptide sequences identiﬁed by phage display for in vitro cell culture (proliferation and
diﬀerentiation). (a) Self-assembled peptide hydrogels functionalized with HAP-binding peptides for periodontal regeneration. (a1) Schematic
illustration of the peptide self-assembly and hydrogel formation. (a2) Fluorescence microscopy image of a live/dead assay on cementoblast cells
encapsulated within self-assembling peptide gels showing viable cells. (a3) Scanning electron microscopy (SEM) image of the peptide gel showing the
deposition of calcium-phosphate mineral by cementoblasts, as conﬁrmed by the corresponding EDXS (inset). Reprinted and adapted with permission
from ref 78. Copyright 2010 Elsevier. (b) BMP-2-binding PA (BMP2b-PA) nanoﬁbers induced osteoblast diﬀerentiation of a myoblast cell line
(C2C12) in vitro. (b1) Photographs of PA-based gels (D-BMP2b-PA: obtained by mixing equal ratios of BMP2b-PA with diluent PA at the same
concentration). (b2) SEMmicrographs of PA gels showing the network of ﬁlamentous nanostructures. (b3) In vitro release of BMP-2 from PA gels, with
or without BMP-2-binding PA, in comparison to collagen sponges preloaded with BMP-2 up to 28 days. (b4) Optical micrographs of C2C12 cells
stained for the detection of ALP on day 3 of culture in a growth medium supplemented with treatment media containing 50 ng mL−1 of BMP-2 with
heparin or PAs at diﬀerent concentrations. Adapted from ref 87. Copyright 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. (c) NSC
diﬀerentiation on 3D peptide nanoﬁber gel scaﬀolds functionalized with bone marrow binding peptides, BMHPs. (c1−c4) Inverted ﬂuorescence
microscopy images of diﬀerentiating adult mouse NSCs cultured in vitro during 7 days on (c1) 1% Matrigel (positive control), (c2) nonfunctionalized
RADA16 peptide gel (negative control), (c3) RADA16-BMHP1, and (c4) RADA16-BMHP2, stained for cell nuclei (blue), β-tubulin+ (red) for
neurons, and nestin+ (green) for neural progenitors (green). Adapted with permission from ref 83. Copyright 2006 Public Library of Science.
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previously identiﬁed peptide sequences, which interact
with both TGF-β receptors (TβRI-ED and TβRII-ED), to
provide localized and deﬁned spatial signaling to cells.77 As a
proof of concept, they used NMuMG mouse mammary gland
cells to investigate the attachment of cells expressing TGF-β
receptors to the surfaces displaying the TβR-binding pep-
tides. The cells bound to SAMs presenting either peptide
(even at low peptide densities, 4%), but not to the bare
surfaces. They further demonstrated that the functionalized
surfaces activated Smad2/3 nuclear translocation (a hallmark
of TGF-β signaling).
These studies demonstrate the power of phage display to
generate peptides that can be used to regulate signaling pathways
that lead to speciﬁc cell outcomes. Strategies to control the bene-
ﬁcial roles of signaling pathways would be valuable for appli-
cations in RM.
3D Hydrogels for Recreating Speciﬁc (Stem) Cell or
Tissue Environments. Molecular design of biomaterials oﬀers
the opportunity to incorporate peptide ligands that can be
recognized by speciﬁc cell receptors or enzymes, and to control
their spatial and temporal availability for triggering regenerative
events. The incorporation of peptide sequences identiﬁed by
phage display into molecularly designed biomaterials, and in
particular, self-assembling peptide biomaterials, has been
reported by several groups.
Being the major inorganic constituent of bone and teeth,
HAP has received great attention as a target for phage display
experiments. For example, the Sarikaya group identiﬁed a
HAP-binding peptide (Table 1),44 which was then incorpo-
rated into a peptide hydrogel capable of directing the min-
eralization of HAP78 (Figure 3a). Other studies describing
peptides with preferential adsorption to HAP-based materials
Figure 4. The application of phage-derived peptides for in vivo tissue regeneration. (a) In vivo stem cell homing by PCL electrospun meshes
functionalized with E7 peptide with speciﬁc aﬃnity for MSCs. (a1) Confocal microscopy images of peptide-conjugated PCL electrospun meshes
harvested 7 days after implantation in full-thickness articular osteochondral defects in rats and stained by immunoﬂuorescence for speciﬁcMSC (CD44,
CD90, CD105) and inﬂammatory (CD68) markers (green: FITC, blue: Hoeschst33258, red: CD44/CD90/CD105/CD68 counterstained with Cy3 &
Cy5). Reprinted and adapted with permission from ref 51. Copyright 2012 Elsevier. (b) PA molecules displaying binding epitopes for TGFβ-1 support
the regeneration of full thickness chondral defects in articular cartilage. (b1) Surgical and implantation procedure showing (b1.1) full thickness articular
cartilage defects made with a microcuret in rabbit trochlea; (b1.2) microfracture holes through the subchondral bone using a microawl to promote
bleeding into the defect; (b1.3) injected PA gel in the defect (arrow); (b1.4) PA gel labeled with a ﬂuorescent dye contained within the cartilage defects
after injection. (b2) Images of articular cartilage defects after 12 weeks of implantation with (b2.1) 100 ng/mL TGF-β1, (b2.2) ﬁller PA + 100TGF,
(b2.3) 10%TGFBPA + 100TGF, (b2.4) 10%TGFBPA alone. (b3) Microscopy images of tissue sections of articular cartilage defects obtained from
histological and immunohistochemical analysis and stained for GAGs using safranin-O (left panel) and type II collagen (right panel) 12 weeks after
treatment with (b3.1, b3.2) 100 ng/mL TGF-β1, (b3.3, b3.4) ﬁller PA + 100TGF, (b3.5, b3.6) 10%TGFBPA + 100TGF, (b3.7, b3.8) 10% TGFBPA
alone. Reprinted with permission from ref 89. Copyright 2010 United States National Academy of Sciences. (c) An injectable collagen gel containing a
bifunctional peptide (BC-1) with aﬃnity for collagen and BMP-2 enhances retention of BMP-2 and increases ectopic bone formation; (c1) osteogenic
cellular activity, bone area, and bone maturity scored from H&E slides (c2) and by two observers; (c2) histology images (H&E staining) from the rat
ectopic model; (c2.1) 2 μg BMP-2 in 1.5% collagen gel; (c2.2) 2 μg BMP-2 with 50-fold molar excess of BC-1 in 1.5% collagen gel (b, bone zones; c,
collagen zones; cells are stained blue). Adapted with permission from ref 17. Copyright 2010 Public Library of Science.
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have also been reported45,79,80 (Table 1). Peptides with binding
aﬃnity to diﬀerent apatite substrates can be used to direct the
growth of HAP on biomaterials surfaces,81 or to improve the
functional properties of HAP-based scaﬀolds, and thus enhance
bone regeneration.
The Stupp laboratory designed self-assembling peptides,
known as peptide amphiphiles (PAs), for RM applications.
Of particular interest for the purpose of this review are PAs
designed to bind GFs using peptide sequences derived by phage
display. They ﬁrst reported a novel class of reverse PAs to enable
the creation of peptide assemblies with a free N-terminus, which
were not possible to obtain through the original design. They
were able to apply this new methodology to synthesize PAs
incorporating peptide sequences, derived via phage display
and requiring a free N-terminus, that bind GFs, BMP-2, and
TGF-β (Table 1),62 all involved in stem cell diﬀerentiation.
These PA molecules are known to form nanoﬁbers by self-
assembly (Figure 3b2), which at suﬃciently high concentration is
accompanied by gelation (Figure 3b1). By permitting the direct
binding of the GF to the PA nanoﬁber, gels containing BMP-2
bound to PA allowed prolonged GF retention (Figure 3b3).
When in solution, the BMP-2-bound PA nanoﬁbers induced the
diﬀerentiation of C2C12 premyoblast cells into osteoblasts, as
detected by an increased number of alkaline phosphatase (ALP,
marker for osteoblast diﬀerentiation)-positive cells (Figure 3b4).
The BMHP motif was used by Gelain and co-workers58,82−86
to functionalize self-assembling peptide scaﬀolds for culturing
and controlling neural stem cell (NSC) behavior for ner-
vous tissue regeneration. In their pioneering work,83 they used
BMHP-functionalized self-assembling peptide hydrogel scaﬀolds
for 3D culture of adult mouse NSCs. In diﬀerentiation assays, the
scaﬀolds containing BMPH motifs (BMHP1 and BMHP2,
Figure 3c3,c4) showed β-tubulin+ and nestin+ cells comparable
with those cultured onMatrigel (Figure 3c1). β-Tubulin+ cells on
BMPH scaﬀolds also showed increased branching when com-
pared with nonfunctionalized scaﬀolds (Figure 3c2). These
results demonstrate the ability of these synthetic peptide nano-
ﬁber scaﬀolds to be functionalized with diﬀerent peptide motifs
for the controlled 3D culture of diverse cell types.
Chemically cross-linked hydrogels, such as those composed of
poly(ethylene glycol) (PEG), have been functionalized with dif-
ferent peptide ligands to culture cells in 3D. The Anseth group88
functionalized PEG hydrogels with a basic ﬁbroblast growth
factor (bFGF)-binding peptide, previously selected by phage
display,63 to control GF retention and sustained release for
applications in GF-induced regeneration. To enhance the aﬃnity
of the bound ligand for diﬀusible proteins (e.g., GFs) within the
hydrogel, they synthesized trifunctional peptides and examined
how the molecular structure of the aﬃnity peptides aﬀected their
accessibility and binding using Forster resonance energy transfer.
They then showed that the optimal functionalization strategy
allowed the sustained release of bioactive bFGF able to induce
the in vitro diﬀerentiation of the PC12 pheochromocytoma cell
line. This aﬃnity hydrogel could be manipulated for GF
retention, or delivery, and be easily applied in distinct RM
approaches, such as controlled stem cell diﬀerentiation in vitro or
GF-mediated wound healing in vivo.
Implantable Biomaterials Functionalized with Peptide
Ligands Identiﬁed by Phage Display for Promoting
Endogenous Tissue Repair in Vivo. Tissue regeneration
in vivo can be enhanced by promoting the recruitment and
localization of stem cells into injured tissues and/or stimulating
the function and diﬀerentiation of local stem cells. This can be
achieved by manipulating the properties of the niche (e.g.,
promote angiogenesis or denovo niches) or through the delivery
of active molecular regulators, directly or combined with a
biomaterial, or by using biomaterial sequestering GFs.
Stem Cell Homing. Using polycaprolactone (PCL, an FDA-
approved polymer for medical applications) electrospun meshes
conjugated with phage-derived peptide (E7, Table 1) with
aﬃnity for human-bone-marrow-derived MSCs (hBMMSCs),
Shao and co-workers showed improved recruitment of MSCs
in vivo after implantation in full-thickness articular osteochondral
defects in a rat knee.51 Immunoﬂuorescence staining of harvested
implants (Figure 4a) showed that cells on the E7-conjugated
PCL meshes were mostly positive for CD44, CD90, and CD105
(MSCs surface markers), indicating that the functionalized
scaﬀold could selectively recruit and retain MSC-like cells from
the bone marrow. In contrast, cells in the PCL meshes conju-
gated with the cell adhesive peptide RGD (with no cell spec-
iﬁcity, control) showed lower levels of MSCs surface markers.
CD68 staining was also used to assess the inﬂammatory
response. Results from immunoﬂuorescence staining showed
that there was a high proportion of inﬂammatory cells in the
RGD-conjugated PCL meshes, while CD68+ cells were scarce in
the E7-conjugated scaﬀold, suggesting only a minor inﬂamma-
tory response. For the bare PCL meshes, only few cells could be
detected into the mesh, due to the unfavorable cell adhesion
properties of PCL. The E7 peptide could be further applied for
functionalizing other biomaterials for eﬀective MSC-homing in
stem-cell-based tissue repair strategies.
Controlled Release of Growth Factors (GFs). TGF-β1 is
known to play a critical role in the development, growth, main-
tenance, and repair of articular cartilage. To this end, the Stupp
group designed self-assembled peptide nanoﬁbers for cartilage
regeneration, using a peptide sequence derived by phage display
with binding aﬃnity for TGF-β1 (Table 1).89 When implanted
into a full-thickness chondral defect in a rabbit model (Figure 4b1),
these self-assembled gels were shown to support the regeneration
of articular cartilage (Figure 4b2,b3) with or without the supple-
mentation of TGF-β1, as detected by formation of hyaline-like
tissue (GAGs and collagen II staining, Figure 4b3) within the
defect space.
To promote bone healing, Hamilton et al.17 developed a novel
strategy to deliver osteogenic GFs, such as BMP-2, in a collagen
biomaterial carrier. This carrier contained a bifunctional peptide
(BC-1) that displayed BMP-2 and collagen-binding domains,
both identiﬁed by phage display (Table 1). This strategy allowed
the simultaneous binding of GFs directly to an implantable
biomaterial, without the requirement for any conjugation steps,
thus allowing the controlled delivery of GFs at the implantation
site. To test the ability of this system to promote bone formation
in vivo, the authors injected BMP-2 within a collagen gel, con-
taining or lacking BC-1, into the subcutaneous regions of
Sprague−Dawley rats (rat ectopic bone formation model).
Histological analysis and evaluation of the explants showed
signiﬁcantly higher osteogenic cellular activity, bone area formed,
and bone maturity in the presence of BC-1 (Figure 4c1,c2).
Degenerative joint diseases, such as osteoarthritis (OA), are
characterized by progressive cartilage matrix degradation.
Targeted therapies for damaged articular cartilage can oﬀer the
opportunity for localization of bioactive proteins, such as GFs,
that can enhance the synthesis of a more hyaline-type cartilage.
Toward this challenge, Hubbell’s group described the synthesis
and functionalization of nanoparticles for the release and reten-
tion of drugs inside articular cartilage through the identiﬁcation
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of a peptide speciﬁc for the principal component of the cartilage
matrix (collagen II α1, Table 1).40 After intra-articular injection
in amousemodel, conjugation of the peptide to nanoparticles led
to higher retention of the nanoparticles within the ECM of
articular cartilage (72-fold increase after 48 h) when compared to
nanoparticles functionalized with a nontargeted (control)
peptide. Such an approach could be used to deliver and localize
speciﬁc GFs for cartilage repair.
Nanobiomaterial Carriers Functionalized with Peptide
Ligands Identiﬁed by Phage Display for Genetic
Manipulation of Cells in Vitro and in Vivo. The ﬁeld of
gene therapy for tissue repair and regeneration would beneﬁt
considerably from the isolation of peptides that can target
endocytosing receptors on speciﬁc cells.90 Internalization of
gene delivery systems is a prerequisite for eﬃcient transgene
expression. Peptides that can be internalized by cells are likely to
be useful for nonviral-mediated gene delivery, where some
current systems do not have the ability to enter the cells (e.g.,
polycation−DNA complexes). Gene therapy vectors could be
modiﬁed with speciﬁc peptide ligands and delivered intra-
venously to transfect only speciﬁc cells, thus improving their
eﬃcacy and reducing the toxicity of the process. Therefore, many
research groups have attempted to select cell-binding and cell-
penetrating peptides (“homing peptides”) using phage display
for targeting speciﬁc cell types.91,92
Targeted Gene Therapy. The use of phage display to
identify cell-selective and cell-entry peptides as gene therapy
vectors was ﬁrst reported by Barry and colleagues in 1996.92
They displayed 12- and 20-mer peptide libraries on pIII protein
of fdTET phage and, by screening the libraries on mammalian
cells, isolated cell-binding peptides. This was the ﬁrst demon-
stration that cell-selective peptides could be identiﬁed by
panning peptide phage libraries on cells, without prior infor-
mation on the target receptors. However, in this pioneering
Figure 5. Cell-targeting gene delivery for selective and more eﬃcient in vitro and in vivo gene therapy. (a) Selective transduction of NPCs in adult
C57BL/6 mouse brain by capsid-mutated AdGFPL.VPTQSSG vector. Fluorescence-activated laser scanning microscopy images of brain sections
analyzed by immunohistochemistry after injection of (a1, a2) PEGylated AdGFPL.VPTQSSG, (a3) AdGFPL.HTFEPGV, (a4) AdGFP into the dentate
gyrus of adult mice. Nestin (red ﬂuorescence, a1) and merge (yellow a2). Abbreviations: AdGFP, adenoviral vector that expresses GFP; AdGFPL,
adenoviral vector that expresses GFP-Luc; VPTQSSG, NPC-speciﬁc binding peptide; HTFEPGV, unspeciﬁc peptide; gcl, granular cell layer. Reprinted
and adapted with permission from ref 57. Copyright 2007 John Wiley and Sons. (b) Targeted gene delivery using PAMAM dendrimers functionalized
with MSCs binding peptides. (b1) Fluorescence microscopy images showing intracellular localization of (RITC)-labeled pDNA (red) in MSCs
transfected with native dendrimers (unconjugated, G5) and dendrimers conjugated with four peptide arms [G5-(HAB)4, G5-(LAB)4] as vectors. The
endosomal-lysosomal system was stained with LysoSensor Green DND-189 (green), and the nucleus with DAPI (blue). (b2) Luc gene expression
obtained with dendrimers (native and conjugated with 2, 4, and 8 HAB peptide arms) with and without presaturation of cell receptors by HAB peptide
(0.1 mM). Reprinted with permission from ref 93. Copyright 2010 American Chemical Society. (c) Delivery of siRNA into the skin and cells using
SPACE peptide. (c1) Confocal microscopy images of human umbilical vein endothelial cells (HUVECs; nuclei stained in blue) treated with (c1.1) PBS
(control), (c1.2) FITC-labeled SPACE peptide for 24 h. (c2) Delivery of siRNA in vitro and in vivo. (c2.1) Percentage of knockdown of GFP in
GFP-expressing endothelial cells. (c2.2) Percentage of knockdown of interleukin-10 (IL-10) in mice after 24 h of treatment. Reprinted with permission
from ref 60. Copyright 2011 United States National Academy of Sciences.
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work, they did not demonstrate the delivery of functional genes
to the nucleus of speciﬁc mammalian cells.
In an attempt to develop in situ gene therapy, Schmidt et al.57
identiﬁed peptide ligands (Table 1) that selectively bound to
mouse NPCs from phage display peptide libraries. They
subsequently conjugated the identiﬁed peptides to wild-type
capsid and capsid-mutated adenovirus (Ad) vectors and tested
their targeting potential in vitro and in vivo, respectively. Peptides
were shown to mediate Ad binding and infection of NPCs
in vitro, and selective transduction of NPCs in the brain of adult
C57BL/6 mice, as shown by the presence of nestin (Figure 5a1),
an NPC-speciﬁc marker, colocalized with green ﬂuorescent
protein (GFP; Figure 5a2). Injection of a nonspeciﬁc peptide
failed to transduce cells in the dentate gyrus, as seen by the
absence of GFP expression (Figure 5a3), while injection of wild-
type capsid AdGFP resulted in transduction of non-NPCs, such
as astrocytes and neurons (Figure 5a4).
Using a nonviral vector (poly(amido)amine (PAMAM)
dendrimers) functionalized with bone-targeting peptides,
identiﬁed by phage display and having high (HAB) and low
(LAB) aﬃnity binding to mouse MSCs, Santos and co-workers93
were able to promote the uptake of plasmid DNA (pDNA) by rat
MSCs (rMSCs). HAB peptide-functionalized dendrimers led to
increased accumulation of pDNA inside cells (Figure 5b1).
In addition, the presence of HAB bone-targeting peptides on the
dendrimer surface led to higher transfection levels than those
obtained with native dendrimers, measured by luciferase (Luc)
gene expression (Figure 5b2). Similarly, Ma and colleagues53
used a rMSC-homing peptide, identiﬁed by phage display
(Table 1), to improve the targeting capability of protamine/
DNA lipoplex (LPD) liposomes to rMSCs for the delivery of the
Sleeping Beauty (SB) transposon plasmid. They also incorpo-
rated the positively charged nuclear localization signal (NLS)
peptide to promote translocation of gene materials into the
nucleus. By combining rMSC-targeting ability and NLS peptide
into LPD liposomes, the transfection eﬃciency was improved,
in comparison to control peptides (randomly selected), by
enhancing the receptor-mediated endocytosis of LPD liposomes
and their accumulation in the nucleus. They showed that the SB
transposon and targeting LPD system did not result in cell
toxicity and did not promote osteogenic diﬀerentiation, sug-
gesting the potential of this system for eﬀective nonviral gene
delivery in stem cell therapy.
By panning on porcine skin, Hsu and Mitragotri60 identiﬁed a
peptide by phage display, named the skin permeating and cell
entering (SPACE) peptide, to enable the diﬀusion of macro-
molecules across the stratum corneum into the epidermis and
dermis. The peptide also showed the ability to translocate the
membrane of skin cells, such as keratinocytes, ﬁbroblasts, and
endothelial cells (Figure 5c1). The eﬃcacy of the peptide to
carry and release small interfering RNA (siRNA) for GFP
(Figure 5c2.1) and IL-10 was tested in vitro and in vivo
(Figure 5c2.2), respectively. Peptide conjugation with siRNA led
to enhanced cell penetration and absorption into the skin and
knockdown of corresponding protein targets. On the contrary,
however, no substantial knockdown was obtained with only
siRNA or SPACE or using control siRNA conjugated with
SPACE or a control peptide.
Using a cartilage aﬃnity peptide (CAP, Table 1) conjugated with
polyethylenimine (PEI) for DNA complexation (CAP-PEI/DNA)
in in vivo cartilage-targeted gene delivery, Pi et al.48 showed that the
CAP-functionalized vector led to a 9-fold higher transfection eﬃ-
ciency in cartilage than the scrambled peptide-conjugated vector.
However, no statistical diﬀerence in the transfection eﬃciency
was observed in the synovium between the vectors modiﬁed with
targeted (CAP) and control (scrambled) peptide.
The identiﬁcation of peptide ligands binding to receptors in
organelles of mammalian cells (Table 1) was recently reported.61
When chemically fused to penetratin, the identiﬁed peptide
was internalized and localized in the mitochondria, promoting
cell death. This study demonstrated the further utility of phage
display for subcellular targeted drug delivery. Advances in
targeted intracellular delivery selectivity also has implications for
RM, namely, inRNA interference (RNAi)-based anabolic therapies,
such as the delivery of osteogenic siRNAs speciﬁcally to osteoblasts
(bone cells), aimed at promoting bone formation.94,95
Imaging Probes Functionalized with Peptide Ligands
Identiﬁedby PhageDisplay for Targeted Imaging of Cells
and Tissues in Vitro and in Vivo. Clinical imaging is an
essential tool in RM. First, it is important to characterize the
status of the damaged/diseased tissue for pretreatment planning,
and second, it is necessary to evaluate the risks and eﬃcacy of the
therapy (post-transplant assessment).96
Injured and Regenerating Host Environment. The environ-
ment in injured or diseased tissues is not favorable for trans-
planted cells. Some tissues produce scars (e.g., ﬁbrotic scar, glial
scar) after injury, and this scarring process prevents engraftment
of stem cells with the neighboring tissues. Additional factors that
contribute for a hostile condition in damaged tissues include the
presence of inﬂammatory cytokines and limited oxygen and
nutrient delivery. Aging of the stem cell niche and corresponding
alteration of the acellular components can cause a loss of
stem cell functionality. Thus, imaging of the niche properties,
including tissue architecture (structural integrity/morphological
alterations) and molecular and cellular composition (e.g., ECM,
GFs, cell populations), could be beneﬁcial for ensuring that
cells are hosted in a healthy environment (non-necrotic tissues).
Peptides can be combined with ﬂuorophores or radioisotopes for
the development of new probes,97 as they provide numerous
beneﬁts over antibodies; they have higher stability and lower
immunogenicity and diﬀuse faster (owing to their small size
allowing better tissue penetration) and are easier to synthesize.
Peptide sequences binding to major components of the ECM
of tissues, such as collagen and HA (Table 1), have been iden-
tiﬁed by phage display. These sequences have been further
developed into molecular probes to detect these macromolecules
in diﬀerent tissues (e.g., pericardium, skin).
HA plays a central role in the wound healing process and
inﬂuences stem cell behavior.98,99 The HA-binding peptide,
described as Pep-1 in the literature, has been biotinylated for
identiﬁcation of HA in the skin.42
To improve the aﬃnity of a phage-derived collagen-binding
peptide for detecting collagen I in tissues, and to improve
contrast/detection, the Meijer group proposed a new approach
to display phage-derived peptides on dendritic architectures.18,38
In this system, a dendron mimics the pentavalent head of the
phage (Figure 6a1). The system was then tested using a collagen-
speciﬁc 7-mer peptide against collagen type I from rat tails.38
Pentavalent display of collagen-binding peptides on dendrimer
wedges enhanced the aﬃnity for collagen 100-fold when com-
pared with the monovalent peptide,38 allowing selective staining
of collagen in tissues containing collagen arranged in diﬀerent
levels of organization (ﬁbrils, ﬁbers, ﬁber bundles). Using 0.6 μM
ﬂuorescein-labeled pentameric peptide on pig parietal pericar-
dium, a highly deﬁned ﬁbrous network with ﬁbers of 2 μm in
thickness was observed (Figure 6a2). This result demonstrates
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that the identiﬁed peptide, derived from rat collagen, also binds
to collagen of diﬀerent species. The monovalent form of the
collagen binding peptide at the same concentration (Figure 6a3)
did not allow collagen detection. Comparable collagen ﬁbrillar
structures were visualized as for the pentameric peptide when
using 60 μM of the monovalent peptide, but the intensity of
background ﬂuorescence was higher (Figure 6a4). A naturally
occurring collagen binding protein (CNA35) was used as a
comparison with the ﬂuorescein-labeled pentavalent peptide.
Both probes allowed visualization of collagen ﬁbers with the
Figure 6. The application of phage-derived peptides for targeted imaging of cells and tissues in vitro and in vivo. (a) Collagen-I-speciﬁc probe based on
collagen-binding peptide displayed on dendrimer edges. (a1) Collagen-binding peptide displayed on dendrimer edges resembling the typical
pentavalent structure of phages. Laser scanning confocal microscopy images of pig parietal pericardium incubated with (a2) 0.6 μM ﬂuorescein-labeled
peptide pentamer, (a3, a4) ﬂuorescein-labeled monovalent collagen binding peptide at 0.6 μM and 60 μM, (a5−a7) 6 μM AlexaFluor568-labeled
CNA35 (red) followed by 0.6 μM ﬂuorescein-labeled peptide pentamer (green) (costaining). Adapted with permission from ref 38. Copyright 2009
American Chemical Society. (b) Detection of VCAM-1 by MRI and ﬂuorescence imaging using VCAM-1-binding peptide (VP) and multimodal
nanoparticles (VNPs) in atherosclerotic lesions. Intravital confocal microscopy images of mouse ear with (b1, b3) or without (b2, b4) mTNF-α-induced
inﬂammation at 4 (b1, b2) and 24 h (b3, b4) after intravenous injection of VNP (red). Green color in the images is due to the tissue autoﬂuorescence.
Images obtained from the 3D stack reconstruction of the Z series (b5) from b3 and of the time series (b6) of VNP staining within the vessels (each time
point is shown as an individual slice in the Z direction and the level of peptide staining (low to high) is given by the color scheme (blue to green)). In vivo
(b7) and ex vivo (b8) MRI of the aorta of cholesterol-fed apoE−/−mice using gadolinium-protected graft copolymer (Gd-PGC) shows deﬁned vascular
lumen and aortic abnormalities such as narrowing (b7, arrows) and low signal changes caused by VNP localization (arrows, b8). (b9) Epiﬂuorescence
image of excised aorta using ﬂuorescent labeled peptide conﬁrming details observed in b8. (b10, b11) Immunoﬂuorescence images of aorta sections
revealing colocalization of VCAM-1 (green) and VNP (red). Nuclei in b10 and b11 are stained with DAPI (blue). Bars = 10 μm. Adapted with
permission from ref 67. Copyright 2005 Lippincott Williams and Wilkins/Wolters Kluwer Health. (c) Targeted imaging of ESCs using peptide-
conjugated QDs. (c1) Schematic of CdSe-ZnS QDs conjugated with APWHLSSQYSRT peptide (green sphere). (c2) Fluorescence and bright-ﬁeld
microscopy images of ESCs (cell nuclei in blue, Hoechest 33258) after incubation with peptide-QDs (red) showing their binding to ESC colonies
(inside dashed line). (c3) Fluorescence microscopy image of peptide QDs with PMEF cells which are used as a feeder layer (outside dashed line).
(c4, c6) Fluorescence microscopy images of cells with free QDs (without conjugated peptides, control). (c5) Fluorescence microscopy images mESCs
peptide-conjugated QDs. Adapted with permission from ref 56. Copyright 2010 Public Library of Science.
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same orientation, but the pentameric peptide led to a more
speciﬁc stain when compared to CNA35 (Figure 6a5−a7).
Optical and nuclear imaging agents could be coupled to
ECM-binding peptides to allow clinical imaging and characterize
organ/tissue morphology (e.g., degraded matrix) before and
after the therapies (matrix formation as a result of regeneration).
Lee and collaborators reported the results of panning against
stabilin-264 (Table 1), known to be produced by activatedmacro-
phages and also strongly expressed in smooth muscle cells and
endothelial cells of atherosclerotic lesions. The identiﬁed pep-
tide sequence was found to bind speciﬁcally to stabilin-2 and
localize to atherosclerotic plaques in vivo. In addition, the pep-
tide was conjugated with ﬂuorescently tagged glycol chitosan
nanoparticles and administered to apolipoprotein E-deﬁcient
mice through direct injection into the left ventricles. The
peptide-conjugated nanoparticles were found to accumulate in
the atherosclerotic lesions, while control nanoparticles were not
visible. These studies revealed peptide ligands that can be used
for selective molecular imaging of atherosclerosis.
Phage display-derived vascular adhesion molecule 1 (VCAM-1)-
speciﬁc peptide has allowed targeted imaging of activated endo-
thelium under inﬂammatory conditions by ﬂuorescence imaging
andmagnetic resonance imaging (MRI, Figure 6b) and has enabled
the visualization of structural abnormalities in the aortic wall.67
Similar probes could be developed against pro-inﬂammatory cyto-
kines implicated in tissue injury (e.g., tumor necrosis factor α
(TNF-α); interleukin 1-β (IL-1β)) to characterize tissue func-
tionality and delineate the feasibility of the cell therapy.
Phage-derived peptides would be also useful to measure
regeneration outcomes, such as angiogenesis and formation of
new tissue. For example, angiogenic vasculature has been
assessed by imaging the binding of RGD-containing peptides
conjugated to PET imaging agents to speciﬁc integrins on the cell
surface.100 Using the above-described probes, the production and
structure of tissue-speciﬁc ECM components (e.g., collagen II
in cartilage or HAP in bone or tooth) could be visualized inde-
pendently and noninvasively through diﬀerent imaging modes.
Similarly, the functionality of newly formed tissue could be
detected by assessing the presence of speciﬁc cell populations
using ligands for phenotype-speciﬁc markers. The discovery of
novel peptide ligands for the development of molecular imaging
probes with enhanced speciﬁcity for detecting constant changes
in the environment of damaged and regenerating tissues would
greatly beneﬁt cell-based therapies.
Cell Labeling/Tracking. Tracking the distribution, function,
and fate of transplanted cells using noninvasive imaging is an
important goal in RM. The ability to assess cell localization,
viability, growth, diﬀerentiation, and engraftment in the host
would be extremely valuable. However, cells administered into
humans cannot be tracked unless they are ﬁrst labeled in vitro.
Cells can be labeled directly, using chemical agents, or indirectly,
by inclusion of reporter genes. Cell labeling methods should be
speciﬁc, nontoxic, and stable (i.e., label agents should remain in
the target cells for suitable periods of time to allow correlation
with cell numbers).
Several cell-binding peptides have been identiﬁed, with the
isolation of stem-cell binding peptides being of particular util-
ity for RM applications100 (Table 1). These peptides can be
exploited for cell labeling/imaging and isolation purposes.
For example, Ma’s group54−56,59 used phage-derived cell-binding
peptides conjugated with quantum dots (QDs, light emitting
agents) to speciﬁcally label ESCs. By panning on rhesus
macaque ESCs, they identiﬁed the sequence, APWHLSSQYSRT
(Table 1), with high aﬃnity for undiﬀerentiated ESCs. They
subsequently conjugated the peptide to CdSe-ZnS QDs
(Figure 6c1) and showed that the conjugates could bind
eﬃciently and selectively to ESCs, with no binding observed
for other cell types (primary mouse embryonic ﬁbroblast,
PMEF, Figure 6c3) and ESCs from other species (mouse ESCs,
Figure 6c5), or when control QDs were used (Figure 6c4,c6).
The E7 peptide (Table 1), known to bind hMSCs, was con-
jugated to gadolinium(Gd)-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) for labeling MSCs for
MRI.101 In vitro studies showed Gd-DOTA-E7 yielded minimum
labeling eﬃcacy but good contrast enhancement.
Identiﬁcation of peptides that interact with stage-speciﬁc
cellular targets (e.g., diﬀerentiation stage) would be useful for
assessing molecular proﬁles of cells in vivo (e.g., imaging diﬀer-
entiation of transplanted cells). Zhao et al.59 identiﬁed a peptide
with the ability to bind NSCs derived from rhesus monkey ESCs
and used this peptide combined with QDs for cell imaging. This
study described for the ﬁrst time the use of phage-derived
peptides for studying ESC diﬀerentiation by optical imaging.
A problem with these imaging agents is that the signal cannot
be used to distinguish live from dead cells, and it is not certain
whether or not these probes will be retained by cells in the long
term. Previous studies indicated that after cell death, contrast
agents can be passed to host cells, producing false positives.102,103
Thus, monitoring stem cell fate may require a combination
of complementary imaging methods, such as ﬂuorescence and
magnetic resonance, to allow the correlation between anatomical
localization of labeled stem cells and cell viability. Reporter genes
represent a potential solution to this issue, although this can pose
additional safety and regulatory problems. Phage display could
also contribute toward the development of molecular probes
that would bind only viable cells resulting in the release of the
label after cell death. Since dead cells have a compromised cell
membrane, it might be possible to identify a speciﬁc ligand for
live cells by panning on dead cells ﬁrst (preclearing).
■ CONCLUDING REMARKS AND OUTLOOK
The ability to display a large and highly diverse collection of
random peptide sequences on the coat proteins of phages oﬀers
the possibility to discover new interactions with useful targets,
often without knowing their structure. The ﬁeld of phage display
technology has evolved signiﬁcantly from when it was ﬁrst
developed for mapping interactions between proteins and has
expanded into other areas that beneﬁt from the discovery of new
interacting ligands. This review demonstrates the usefulness of
phage display in the emerging ﬁeld of RM, suggesting oppor-
tunities for further applications. However, we must consider the
challenges associated with phage-derived peptides before their
translation into useful RM tools. When used as linear monomers,
isolated peptide ligands usually show poor aﬃnity for their
targets, as this presentation diﬀers signiﬁcantly from the original
display (valency and orientation) on the phage particles. Multi-
merization (conjugation of multiple peptide copies to a surface of
a nanoparticle, like dendrimers, liposomes, or micelles) has been
proven to increase aﬃnity of the ligand for its targets, but the
aﬃnity of these multivalent peptide platforms also depends on
the density of receptors on the cell periphery. In addition, when
displayed on the phage, peptides are fused to the coat protein
through the C-terminus and have a free N-terminus. This feature
is not always taken into account when presenting phage-derived
peptides intomultivalent carriers. This stresses the importance of
the use of biomaterials engineering to enable the peptides to be
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displayed in the precise and optimal multimeric conformation for
interaction with cell receptors. Presenting peptides within a
biomaterials platform also provides protection against proteolytic
degradation, which is essential for prolonging their half-life in vivo.
It should be noted that many of the sequences described in this
review were obtained from targets derived frommultiple species.
Thus, it is necessary to conﬁrm if these peptides also bind to the
same targets in humans. Although cell-binding peptides can be
used without knowing their speciﬁc receptors, identiﬁcation of
their cellular targets is essential for gaining clinical approval, as
emphasized by Gray and Brown.100 It is also useful for obtaining
information about the heterogeneity of the protein repertoire on
the cell surface and how it varies among cell types and states.
To accelerate the safe application of phage-derived peptides
within the ﬁeld of RM, the next logical steps will be their further
optimization and validation in vitro and in vivo, in terms of
aﬃnity, speciﬁcity, activity, stability, and biodistribution.
While binding has been the basis for peptide screening in
phage display, selection based on function might be useful
for certain RM approaches (e.g., controlled stem cell diﬀer-
entiation). In a recent perspective article,104 Lerner highlighted
the potential of intracellular combinatorial (unbiased) antibody
libraries as a discovery tool to select antibodies able to bind
unknown receptors or to identify new roles of common recep-
tors. They showed that infection of BMSCs with unbiased
libraries led to the selection of various antibody agonists that
induced proliferation of cells, or proliferation followed by diﬀer-
entiation or trans-diﬀerentiation into neural cells, indicating dif-
ferent roles for identiﬁed receptors in diﬀerentiation. These
studies suggest new ways to regulate cell fates by selecting cell-
binding antibodies or peptides on the basis of function (e.g., ability
to activate a given receptor involved in inducing diﬀerentiation).
With further advances in biology and RM, there are enormous
opportunities for phage display to contribute tools for research
and applications in such ﬁelds. Led by a vibrant research
community in biology and RM, phage display technology will
have a broad range of applications in the future.
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■ KEYWORDS
Bacteriophages (or phages): viruses that speciﬁcally infect
bacterial cells and consist of an outer protein capsid enclosing
genetic material (dsDNA - vast majority; ssDNA; ssRNA; or
dsRNA - very rare; with either circular or linear arrangement)
Biomaterials: synthetic or natural materials designed to
interact with tissues and organs in the body to monitor and/or
restore their functions
Nanotechnology: technology that involves imaging, measur-
ing, modeling, and manipulating materials on the nanometer
scale (i.e., 10−9 m), typically in the range of 1 to 100 nm
Peptide ligand: a peptide sequence which binds with high
aﬃnity and speciﬁcity to a particular target
Phage display panning: combinatorial process of displaying
random peptide sequences or engineered proteins, fused to
the coat proteins on the surface of phages, to identify peptides
or proteins (out of billions of candidates) that bind speciﬁcally
and selectively to a deﬁned or unknown target
Phage display peptide library: collection of phage particles
displaying random peptides containing as many as 109
combinations
Regenerative medicine: new ﬁeld in the health sciences
dedicated to the regeneration of tissues or organs by applying
speciﬁc cell populations or biomaterial scaﬀolds, alone or
combined, to stimulate the intrinsic healing ability of the body
and promote endogenous repair
Targeted delivery: method of delivering a therapeutic (drug,
bioactive protein, or gene) or imaging (probe) agent to a
speciﬁc site in the body, which optimizes its therapeutic or
imaging index by restricting its pharmacological or imaging
activity to the target tissue or organ, and reducing potential
exposure in unwanted sites
Ad: adenovirus
ALP: alkaline phosphatase
ASCs: adipose stromal cells
ATs: alkanethiols
BC-1: bifunctional peptide 1
bFGF: basic ﬁbroblast growth factor
BMHP: bone marrow homing peptide
BMP-2: bone morphogenetic protein 2
BMSCs: bone marrow stem cells
BRASIL: biopanning and rapid analysis of selective interactive
ligands
C3: complement 3
CAP: chondrocyte-aﬃnity peptide
cBMHP: cyclic BMHP
cDNA: complementary DNA
Col: collagen
DMEM: Dulbecco’s modiﬁed eagle medium
DNA: DNA
DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid
ds: double stranded
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EC50: half maximal eﬀective concentration
ECM: extracellular matrix
ELISA: enzyme-linked immunosorbent assay
ESCs: embryonic stem cells
FDA: U.S. Food and Drug Administration
FITC: ﬂuorescein isothiocyanate
GAG: glycosaminoglycan
Gd-PGC: gadolinium-protected graft copolymer
GF: growth factor
GFP: green ﬂuorescent protein
HA: hyaluronic acid (or hyaluronan)
HAB: high aﬃnity binding
hACs: human articular chondrocytes
HAP: hydroxyapatite
H&E: hematoxylin and eosin
HUVECs: human umbilical vein endothelial cells
IC50: half inhibitory concentration
IL-1: interleukin 1
IL-10: interleukin 10
KD: dissociation constant
LAB: low aﬃnity binding
MRI: magnetic resonance imaging
mRNA: mRNA
MSCs: mesenchymal stem cells
mTNF-α: murine TNF-α
NGS: next generation sequencing
NLS: nuclear localization signal
NPCs: neural progenitor cells
NSCs: neural stem cells
OA: osteoarthritis
ODM: osteogenic diﬀerentiation medium
PA: peptide amphiphile
PAMAM: poly(amido)amine
PCL: polycaprolactone
pDNA: plasmid DNA
PEG: polyethylene glycol
PEI: polyethylenimine
PET: positron emission tomography
PMEF: primary mouse embryonic ﬁbroblast
QDs: quantum-dots
RGD: arginine-glycine-aspartic acid
RHAMM: receptor for hyaluronan-mediated motility
rhBMP-2: recombinant form of human BMP-2
RM: regenerative medicine
rMSC: rat MSCs
RNA: ribonucleic acid
RNAi: RNA interference
S2P: stabilin-2 peptide
SA: streptavidin
SAM: self-assembled monolayer
SEM: scanning electron microscopy
siRNA: small interfering RNA
SPACE: skin permeating and cell entering
ss: single stranded
TGF-β: transforming growth factor β
TGF-βR: transforming growth factor β receptor
TNF: tumor necrosis factor
VCAM-1: vascular cell adhesion molecule 1
VNP: VHSPNKK-modiﬁed magnetoﬂuorescent nanoparticle
■ REFERENCES
(1)Mason, C., and Dunnill, P. (2008) A brief definition of regenerative
medicine. Regener. Med. 3, 1−5.
(2) Smith, G. P. (1985) Filamentous fusion phage: novel expression
vectors that display cloned antigens on the virion surface. Science 228,
1315−1317.
(3) Deutscher, S. L. (2010) Phage display in molecular imaging and
diagnosis of cancer. Chem. Rev. 110, 3196−3211.
(4) Hamzeh-Mivehroud, M., Alizadeh, A. A., Morris, M. B., Church, W.
B., and Dastmalchi, S. (2013) Phage display as a technology delivering
on the promise of peptide drug discovery. Drug Discovery Today 18,
1144−1157.
(5) Krumpe, L. R., and Mori, T. (2006) The Use of Phage-Displayed
Peptide Libraries to Develop Tumor-Targeting Drugs. Int. J. Pept. Res.
Ther. 12, 79−91.
(6) Smith, G. P., and Petrenko, V. A. (1997) Phage Display. Chem. Rev.
97, 391−410.
(7) Petrenko, V. (2008) Evolution of phage display: from bioactive
peptides to bioselective nanomaterials. Expert Opin. Drug Delivery 5,
825−836.
(8) Shiba, K. (2010) Exploitation of peptide motif sequences and their
use in nanobiotechnology. Curr. Opin. Biotechnol. 21, 412−425.
(9) Wilson, D. R., and Finlay, B. B. (1998) Phage display: applications,
innovations, and issues in phage and host biology. Can. J. Microbiol. 44,
313−329.
(10) Bratkovic, T. (2010) Progress in phage display: evolution of the
technique and its application. Cell. Mol. Life Sci. 67, 749−767.
(11) Pande, J., Szewczyk, M. M., and Grover, A. K. (2010) Phage
display: concept, innovations, applications and future. Biotechnol. Adv.
28, 849−858.
(12) Paschke, M. (2006) Phage display systems and their applications.
Appl. Microbiol. Biotechnol. 70, 2−11.
(13) Sergeeva, A., Kolonin, M. G., Molldrem, J. J., Pasqualini, R., and
Arap, W. (2006) Display technologies: application for the discovery of
drug and gene delivery agents. Adv. Drug Delivery Rev. 58, 1622−1654.
(14) Smothers, J. F., Henikoff, S., and Carter, P. (2002) Phage display:
Affinity selection from biological libraries. Science 298, 621−622.
(15) Barbas, C. F., Burton, D. R., Scott, J. K., and Silverman, G. J.
(2001) Phage Display: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, New York.
(16) Clarkson, T., and Lowman, H. B. (2004) Phage Display: A
Practical Approach, Oxford University Press, Oxford.
(17) Hamilton, P. T., Jansen, M. S., Ganesan, S., Benson, R. E., Hyde-
Deruyscher, R., Beyer, W. F., Gile, J. C., Nair, S. A., Hodges, J. A., and
Gron, H. (2013) Improved bone morphogenetic protein-2 retention in
an injectable collagen matrix using bifunctional peptides. PLoS One 8,
e70715.
(18) Bastings, M. M., Helms, B. A., van Baal, I., Hackeng, T. M., Merkx,
M., and Meijer, E. W. (2011) From phage display to dendrimer display:
insights into multivalent binding. J. Am. Chem. Soc. 133, 6636−6641.
(19) Hajduczki, A., Majumdar, S., Fricke, M., Brown, I. A., and Weiss,
G. A. (2011) Solubilization of a membrane protein by combinatorial
supercharging. ACS Chem. Biol. 6, 301−307.
(20) Giordano, R. J., Cardo-Vila, M., Lahdenranta, J., Pasqualini, R.,
and Arap, W. (2001) Biopanning and rapid analysis of selective
interactive ligands. Nat. Med. 7, 1249−1253.
(21) Derda, R., Musah, S., Orner, B. P., Klim, J. R., Li, L., and Kiessling,
L. L. (2010) High-throughput discovery of synthetic surfaces that
support proliferation of pluripotent cells. J. Am. Chem. Soc. 132, 1289−
1295.
(22) Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardo-Vila,
M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., Chen,
L., Flamm, A., Valtanen, H., Weavind, L. M., Hicks, M. E., Pollock, R. E.,
Botz, G. H., Bucana, C. D., Koivunen, E., Cahill, D., Troncoso, P.,
Baggerly, K. A., Pentz, R. D., Do, K. A., Logothetis, C. J., and Pasqualini,
R. (2002) Steps toward mapping the human vasculature by phage
display. Nat. Med. 8, 121−127.
(23) Chen, Y., Shen, Y., Guo, X., Zhang, C., Yang, W., Ma, M., Liu, S.,
Zhang, M., and Wen, L. P. (2006) Transdermal protein delivery by a
coadministered peptide identified via phage display. Nat. Biotechnol. 24,
455−460.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b00717
ACS Chem. Biol. 2016, 11, 2962−2980
2977
(24) Pasqualini, R., and Ruoslahti, E. (1996) Organ targeting in vivo
using phage display peptide libraries. Nature 380, 364−366.
(25) Trepel, M., Arap, W., and Pasqualini, R. (2002) In vivo phage
display and vascular heterogeneity: implications for targeted medicine.
Curr. Opin. Chem. Biol. 6, 399−404.
(26) Nowakowski, G. S., Dooner, M. S., Valinski, H. M., Mihaliak, A.
M., Quesenberry, P. J., and Becker, P. S. (2004) A specific heptapeptide
from a phage display peptide library homes to bonemarrow and binds to
primitive hematopoietic stem cells. Stem Cells 22, 1030−1038.
(27) Matochko, W. L., Chu, K., Jin, B., Lee, S. W., Whitesides, G. M.,
and Derda, R. (2012) Deep sequencing analysis of phage libraries using
Illumina platform. Methods 58, 47−55.
(28) t Hoen, P. A. C., Jirka, S. M., Ten Broeke, B. R., Schultes, E. A.,
Aguilera, B., Pang, K. H., Heemskerk, H., Aartsma-Rus, A., van Ommen,
G. J., and den Dunnen, J. T. (2012) Phage display screening without
repetitious selection rounds. Anal. Biochem. 421, 622−631.
(29) Ernst, A., Gfeller, D., Kan, Z., Seshagiri, S., Kim, P. M., Bader, G.
D., and Sidhu, S. S. (2010) Coevolution of PDZ domain-ligand
interactions analyzed by high-throughput phage display and deep
sequencing. Mol. BioSyst. 6, 1782−1790.
(30) Rentero Rebollo, I., Sabisz, M., Baeriswyl, V., and Heinis, C.
(2014) Identification of target-binding peptide motifs by high-
throughput sequencing of phage-selected peptides. Nucleic Acids Res.
42, e169.
(31) Robins, W. P., Faruque, S. M., and Mekalanos, J. J. (2013)
Coupling mutagenesis and parallel deep sequencing to probe essential
residues in a genome or gene. Proc. Natl. Acad. Sci. U. S. A. 110, E848−
857.
(32) Zhang, H., Torkamani, A., Jones, T. M., Ruiz, D. I., Pons, J., and
Lerner, R. A. (2011) Phenotype-information-phenotype cycle for
deconvolution of combinatorial antibody libraries selected against
complex systems. Proc. Natl. Acad. Sci. U. S. A. 108, 13456−13461.
(33) Huang, J., Ru, B., and Dai, P. (2011) Bioinformatics resources and
tools for phage display. Molecules 16, 694−709.
(34) Huang, J., Ru, B., Zhu, P., Nie, F., Yang, J., Wang, X., Dai, P., Lin,
H., Guo, F. B., and Rao, N. (2012) MimoDB 2.0: a mimotope database
and beyond. Nucleic Acids Res. 40, 271−277.
(35) Sahu, A., Kay, B. K., and Lambris, J. D. (1996) Inhibition of
human complement by a C3-binding peptide isolated from a phage-
displayed random peptide library. J. Immunol 157, 884−891.
(36) Ricklin, D., and Lambris, J. D. (2008) Compstatin: a complement
inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632, 262−
281.
(37) Nilsson, B., Ekdahl, K. N., Mollnes, T. E., and Lambris, J. D.
(2007) The role of complement in biomaterial-induced inflammation.
Mol. Immunol. 44, 82−94.
(38) Helms, B. A., Reulen, S. W., Nijhuis, S., de Graaf-Heuvelmans, P.
T., Merkx, M., and Meijer, E. W. (2009) High-affinity peptide-based
collagen targeting using synthetic phage mimics: from phage display to
dendrimer display. J. Am. Chem. Soc. 131, 11683−11685.
(39) Gron, H., and Duﬃn, D. Methods and compositions for
promoting localization of pharmaceutically active agents to bone. Patent
2008/0268015A1, 2008.
(40) Rothenfluh, D. A., Bermudez, H., O’Neil, C. P., and Hubbell, J. A.
(2008) Biofunctional polymer nanoparticles for intra-articular targeting
and retention in cartilage. Nat. Mater. 7, 248−254.
(41) Chan, J. M., Zhang, L., Tong, R., Ghosh, D., Gao, W., Liao, G.,
Yuet, K. P., Gray, D., Rhee, J. W., Cheng, J., Golomb, G., Libby, P.,
Langer, R., and Farokhzad, O. C. (2010) Spatiotemporal controlled
delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. U. S.
A. 107, 2213−2218.
(42) Mummert, M. E., Mohamadzadeh, M., Mummert, D. I.,
Mizumoto, N., and Takashima, A. (2000) Development of a peptide
inhibitor of hyaluronan-mediated leukocyte trafficking. J. Exp. Med. 192,
769−779.
(43) Roy, M. D., Stanley, S. K., Amis, E. J., and Becker, M. L. (2008)
Identification of a highly specific hydroxyapatite-binding peptide using
phage display. Adv. Mater. 20, 1830−1836.
(44) Gungormus, M., Fong, H., Kim, I. W., Evans, J. S., Tamerler, C.,
and Sarikaya, M. (2008) Regulation of in vitro calcium phosphate
mineralization by combinatorially selected hydroxyapatite-binding
peptides. Biomacromolecules 9, 966−973.
(45) Chung, W. J., Kwon, K. Y., Song, J., and Lee, S. W. (2011)
Evolutionary screening of collagen-like peptides that nucleate
hydroxyapatite crystals. Langmuir 27, 7620−7628.
(46) Li, Z., Fan, J., Zhao, W., Jin, L., and Ma, L. (2011) The specific
binding of peptide ligands to cardiomyocytes derived from mouse
embryonic stem cells. J. Pept. Sci. 17, 771−782.
(47) Cheung, C. S., Lui, J. C., and Baron, J. (2013) Identification of
chondrocyte-binding peptides by phage display. J. Orthop. Res. 31,
1053−1058.
(48) Pi, Y., Zhang, X., Shi, J., Zhu, J., Chen, W., Zhang, C., Gao, W.,
Zhou, C., and Ao, Y. (2011) Targeted delivery of non-viral vectors to
cartilage in vivo using a chondrocyte-homing peptide identified by
phage display. Biomaterials 32, 6324−6332.
(49) Nie, J., Chang, B., Traktuev, D. O., Sun, J., March, K., Chan, L.,
Sage, E. H., Pasqualini, R., Arap, W., and Kolonin, M. G. (2008) IFATS
collection: Combinatorial peptides identify alpha5beta1 integrin as a
receptor for the matricellular protein SPARC on adipose stromal cells.
Stem Cells 26, 2735−2745.
(50) Daquinag, A. C., Zhang, Y., Amaya-Manzanares, F., Simmons, P.
J., and Kolonin, M. G. (2011) An isoform of decorin is a resistin receptor
on the surface of adipose progenitor cells. Cell Stem Cell 9, 74−86.
(51) Shao, Z., Zhang, X., Pi, Y., Wang, X., Jia, Z., Zhu, J., Dai, L., Chen,
W., Yin, L., Chen, H., Zhou, C., and Ao, Y. (2012) Polycaprolactone
electrospun mesh conjugated with an MSC affinity peptide for MSC
homing in vivo. Biomaterials 33, 3375−3387.
(52) Balian, G. Bone Targeting Peptides. Patent 7,323,542, 2008.
(53) Ma, K., Wang, D. D., Lin, Y., Wang, J., Petrenko, V., and Mao, C.
(2013) Synergetic Targeted Delivery of Sleeping-Beauty Transposon
System toMesenchymal StemCells Using LPDNanoparticles Modified
with a Phage-Displayed Targeting Peptide. Adv. Funct. Mater. 23, 1172−
1181.
(54) Zhao, W., Jin, L., Yuan, H., Tan, Z., Zhou, C., Li, L. S., and Ma, L.
(2013) Targeting human embryonic stem cells with quantum dot-
conjugated phages. Sci. Rep. 3, 3134.
(55) Zhao, S., Zhao, W., and Ma, L. (2010) Novel peptide ligands that
bind specifically to mouse embryonic stem cells. Peptides 31, 2027−
2034.
(56) Lu, S., Xu, X., Zhao, W., Wu, W., Yuan, H., Shen, H., Zhou, C., Li,
L. S., and Ma, L. (2010) Targeting of embryonic stem cells by peptide-
conjugated quantum dots. PLoS One 5, e12075.
(57) Schmidt, A., Haas, S. J., Hildebrandt, S., Scheibe, J., Eckhoff, B.,
Racek, T., Kempermann, G., Wree, A., and Putzer, B. M. (2007)
Selective targeting of adenoviral vectors to neural precursor cells in the
hippocampus of adult mice: new prospects for in situ gene therapy. Stem
Cells 25, 2910−2918.
(58) Caprini, A., Silva, D., Zanoni, I., Cunha, C., Volonte, C., Vescovi,
A., and Gelain, F. (2013) A novel bioactive peptide: assessing its activity
over murine neural stem cells and its potential for neural tissue
engineering. New Biotechnol. 30, 552−562.
(59) Zhao, W., Yuan, H., Xu, X., and Ma, L. (2010) Isolation and initial
application of a novel peptide that specifically recognizes the neural stem
cells derived from rhesus monkey embryonic stem cells. J. Biomol.
Screening 15, 687−694.
(60) Hsu, T., and Mitragotri, S. (2011) Delivery of siRNA and other
macromolecules into skin and cells using a peptide enhancer. Proc. Natl.
Acad. Sci. U. S. A. 108, 15816−15821.
(61) Rangel, R., Guzman-Rojas, L., le Roux, L. G., Staquicini, F. I.,
Hosoya, H., Barbu, E. M., Ozawa, M. G., Nie, J., Dunner, K., Jr., Langley,
R. R., Sage, E. H., Koivunen, E., Gelovani, J. G., Lobb, R. R., Sidman, R.
L., Pasqualini, R., and Arap, W. (2012) Combinatorial targeting and
discovery of ligand-receptors in organelles of mammalian cells. Nat.
Commun. 3, 788.
(62) Behanna, H. A., Donners, J. J., Gordon, A. C., and Stupp, S. I.
(2005) Coassembly of amphiphiles with opposite peptide polarities into
nanofibers. J. Am. Chem. Soc. 127, 1193−1200.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b00717
ACS Chem. Biol. 2016, 11, 2962−2980
2978
(63) Yayon, A., Aviezer, D., Safran, M., Gross, J. L., Heldman, Y.,
Cabilly, S., Givol, D., and Katchalski-Katzir, E. (1993) Isolation of
peptides that inhibit binding of basic fibroblast growth factor to its
receptor from a random phage-epitope library. Proc. Natl. Acad. Sci. U. S.
A. 90, 10643−10647.
(64) Lee, G. Y., Kim, J. H., Oh, G. T., Lee, B. H., Kwon, I. C., and Kim, I.
S. (2011) Molecular targeting of atherosclerotic plaques by a stabilin-2-
specific peptide ligand. J. Controlled Release 155, 211−217.
(65) Li, L., Orner, B. P., Huang, T., Hinck, A. P., and Kiessling, L. L.
(2010) Peptide ligands that use a novel binding site to target both TGF-
beta receptors. Mol. BioSyst. 6, 2392−2402.
(66) Michon, I. N., Penning, L. C., Molenaar, T. J., van Berkel, T. J.,
Biessen, E. A., and Kuiper, J. (2002) The effect of TGF-beta receptor
binding peptides on smooth muscle cells. Biochem. Biophys. Res.
Commun. 293, 1279−1286.
(67) Kelly, K. A., Allport, J. R., Tsourkas, A., Shinde-Patil, V. R.,
Josephson, L., andWeissleder, R. (2005) Detection of vascular adhesion
molecule-1 expression using a novel multimodal nanoparticle. Circ. Res.
96, 327−336.
(68) Nahrendorf, M., Jaffer, F. A., Kelly, K. A., Sosnovik, D. E., Aikawa,
E., Libby, P., and Weissleder, R. (2006) Noninvasive vascular cell
adhesion molecule-1 imaging identifies inflammatory activation of cells
in atherosclerosis. Circulation 114, 1504−1511.
(69) Yang, B., Yang, B. L., Savani, R. C., and Turley, E. A. (1994)
Identification of a common hyaluronan binding motif in the hyaluronan
binding proteins RHAMM, CD44 and link protein. EMBO J. 13, 286−
296.
(70) Chai, C., and Leong, K. W. (2007) Biomaterials approach to
expand and direct differentiation of stem cells. Mol. Ther. 15, 467−480.
(71) Mallanna, S. K., and Rizzino, A. (2012) Systems biology provides
new insights into the molecular mechanisms that control the fate of
embryonic stem cells. J. Cell. Physiol. 227, 27−34.
(72) da SilvaMeirelles, L., Fontes, A. M., Covas, D. T., and Caplan, A. I.
(2009) Mechanisms involved in the therapeutic properties of
mesenchymal stem cells. Cytokine Growth Factor Rev. 20, 419−427.
(73) Oh, I. H., and Humphries, R. K. (2012) Concise review:
Multidimensional regulation of the hematopoietic stem cell state. Stem
Cells 30, 82−88.
(74) Balian, G., Beck, G., Madhu, V., Sikes, R., Cui, Q., Liang, H., and
Bush, J. (2010) Peptides from phage display library modulate gene
expression in mesenchymal cells and potentiate osteogenesis in
unicortical bone defects. J. Visualized Exp., DOI: 10.3791/2362.
(75) Cao, F. Y., Yin, W. N., Fan, J. X., Zhuo, R. X., and Zhang, X. Z.
(2015) A novel function of BMHP1 and cBMHP1 peptides to induce
the osteogenic differentiation of mesenchymal stem cells. Biomater. Sci.
3, 345−351.
(76) Cabanas-Danes, J., Nicosia, C., Landman, E., Karperien, M.,
Huskens, J., and Jonkheijm, P. (2013) A fluorogenic monolayer to detect
the co-immobilization of peptides that combine cartilage targeting and
regeneration. J. Mater. Chem. B 1, 1903−1908.
(77) Li, L., Klim, J. R., Derda, R., Courtney, A. H., and Kiessling, L. L.
(2011) Spatial control of cell fate using synthetic surfaces to potentiate
TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 108, 11745−11750.
(78) Gungormus, M., Branco, M., Fong, H., Schneider, J. P., Tamerler,
C., and Sarikaya, M. (2010) Self assembled bi-functional peptide
hydrogels with biomineralization-directing peptides. Biomaterials 31,
7266−7274.
(79) Segvich, S. J., Smith, H. C., and Kohn, D. H. (2009) The
adsorption of preferential binding peptides to apatite-based materials.
Biomaterials 30, 1287−1298.
(80) Weiger, M. C., Park, J. J., Roy, M. D., Stafford, C. M., Karim, A.,
and Becker, M. L. (2010) Quantification of the binding affinity of a
specific hydroxyapatite binding peptide. Biomaterials 31, 2955−2963.
(81) Jin, H. E., Jang, J., Chung, J., Lee, H. J., Wang, E., Lee, S. W., and
Chung, W. J. (2015) Biomimetic Self-Templated Hierarchical
Structures of Collagen-Like Peptide Amphiphiles. Nano Lett. 15,
7138−7145.
(82) Cigognini, D., Silva, D., Paloppi, S., and Gelain, F. (2014)
Evaluation of Mechanical Properties and Therapeutic Effect of
Injectable Self-Assembling Hydrogels for Spinal Cord Injury. J. Biomed.
Nanotechnol. 10, 309.
(83) Gelain, F., Bottai, D., Vescovi, A., and Zhang, S. (2006) Designer
self-assembling peptide nanofiber scaffolds for adult mouse neural stem
cell 3-dimensional cultures. PLoS One 1, e119.
(84) Gelain, F., Cigognini, D., Caprini, A., Silva, D., Colleoni, B.,
Donega, M., Antonini, S., Cohen, B. E., and Vescovi, A. (2012) New
bioactive motifs and their use in functionalized self-assembling peptides
for NSC differentiation and neural tissue engineering. Nanoscale 4,
2946−2957.
(85) Gelain, F., Panseri, S., Antonini, S., Cunha, C., Donega, M.,
Lowery, J., Taraballi, F., Cerri, G., Montagna, M., Baldissera, F., and
Vescovi, A. (2011) Transplantation of nanostructured composite
scaffolds results in the regeneration of chronically injured spinal cords.
ACS Nano 5, 227−236.
(86) Gelain, F., Silva, D., Caprini, A., Taraballi, F., Natalello, A., Villa,
O., Nam, K. T., Zuckermann, R. N., Doglia, S. M., and Vescovi, A.
(2011) BMHP1-derived self-assembling peptides: hierarchically
assembled structures with self-healing propensity and potential for
tissue engineering applications. ACS Nano 5, 1845−1859.
(87) Lee, S. S., Hsu, E. L., Mendoza, M., Ghodasra, J., Nickoli, M. S.,
Ashtekar, A., Polavarapu, M., Babu, J., Riaz, R. M., Nicolas, J. D., Nelson,
D., Hashmi, S. Z., Kaltz, S. R., Earhart, J. S., Merk, B. R., McKee, J. S.,
Bairstow, S. F., Shah, R. N., Hsu, W. K., and Stupp, S. I. (2015) Gel
scaffolds of BMP-2-binding peptide amphiphile nanofibers for spinal
arthrodesis. Adv. Healthcare Mater. 4, 131−141.
(88) Lin, C. C., and Anseth, K. S. (2009) Controlling Affinity Binding
with Peptide-Functionalized Poly(ethylene glycol) Hydrogels. Adv.
Funct. Mater. 19, 2325.
(89) Shah, R. N., Shah, N. A., Del Rosario Lim, M. M., Hsieh, C.,
Nuber, G., and Stupp, S. I. (2010) Supramolecular design of self-
assembling nanofibers for cartilage regeneration. Proc. Natl. Acad. Sci. U.
S. A. 107, 3293−3298.
(90) Rasmussen, U. B., Schreiber, V., Schultz, H., Mischler, F., and
Schughart, K. (2002) Tumor cell-targeting by phage-displayed peptides.
Cancer Gene Ther. 9, 606−612.
(91) Svensen, N., Walton, J. G., and Bradley, M. (2012) Peptides for
cell-selective drug delivery. Trends Pharmacol. Sci. 33, 186−192.
(92) Barry, M. A., Dower, W. J., and Johnston, S. A. (1996) Toward
cell-targeting gene therapy vectors: selection of cell-binding peptides
from random peptide-presenting phage libraries. Nat. Med. 2, 299−305.
(93) Santos, J. L., Pandita, D., Rodrigues, J., Pego, A. P., Granja, P. L.,
Balian, G., and Tomas, H. (2010) Receptor-mediated gene delivery
using PAMAM dendrimers conjugated with peptides recognized by
mesenchymal stem cells. Mol. Pharmaceutics 7, 763−774.
(94) Liang, C., Guo, B., Wu, H., Shao, N., Li, D., Liu, J., Dang, L., Wang,
C., Li, H., Li, S., Lau, W. K., Cao, Y., Yang, Z., Lu, C., He, X., Au, D. W.,
Pan, X., Zhang, B. T., Lu, C., Zhang, H., Yue, K., Qian, A., Shang, P., Xu,
J., Xiao, L., Bian, Z., Tan, W., Liang, Z., He, F., Zhang, L., Lu, A., and
Zhang, G. (2015) Aptamer-functionalized lipid nanoparticles targeting
osteoblasts as a novel RNA interference-based bone anabolic strategy.
Nat. Med. 21, 288−294.
(95) Zhang, G., Guo, B., Wu, H., Tang, T., Zhang, B. T., Zheng, L., He,
Y., Yang, Z., Pan, X., Chow, H., To, K., Li, Y., Li, D., Wang, X., Wang, Y.,
Lee, K., Hou, Z., Dong, N., Li, G., Leung, K., Hung, L., He, F., Zhang, L.,
and Qin, L. (2012) A delivery system targeting bone formation surfaces
to facilitate RNAi-based anabolic therapy. Nat. Med. 18, 307−314.
(96) Naumova, A. V., Modo, M., Moore, A., Murry, C. E., and Frank, J.
A. (2014) Clinical imaging in regenerative medicine.Nat. Biotechnol. 32,
804−818.
(97) Molek, P., Strukelj, B., and Bratkovic, T. (2011) Peptide phage
display as a tool for drug discovery: targeting membrane receptors.
Molecules 16, 857−887.
(98) Solis, M. A., Chen, Y. H., Wong, T. Y., Bittencourt, V. Z., Lin, Y.
C., and Huang, L. L. (2012) Hyaluronan regulates cell behavior: a
potential niche matrix for stem cells. Biochem. Res. Int. 2012, 346972.
(99) Volk, S. W., Iqbal, S. A., and Bayat, A. (2013) Interactions of the
Extracellular Matrix and Progenitor Cells in CutaneousWoundHealing.
Advances in wound care 2, 261−272.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b00717
ACS Chem. Biol. 2016, 11, 2962−2980
2979
(100) Gray, B. P., and Brown, K. C. (2014) Combinatorial peptide
libraries: mining for cell-binding peptides. Chem. Rev. 114, 1020−1081.
(101) Cao, L., Li, B., Yi, P., Zhang, H., Dai, J., Tan, B., and Deng, Z.
(2014) The interplay of T1- and T2-relaxation on T1-weighted MRI of
hMSCs induced by Gd-DOTA-peptides. Biomaterials 35, 4168−4174.
(102) Barrow, M., Taylor, A., Murray, P., Rosseinsky, M. J., and Adams,
D. J. (2015) Design considerations for the synthesis of polymer coated
iron oxide nanoparticles for stem cell labelling and tracking using MRI.
Chem. Soc. Rev. 44, 6733−6748.
(103) Taylor, A., Wilson, K. M., Murray, P., Fernig, D. G., and Levy, R.
(2012) Long-term tracking of cells using inorganic nanoparticles as
contrast agents: are we there yet? Chem. Soc. Rev. 41, 2707−2717.
(104) Yea, K., Xie, J., Zhang, H., Zhang, W., and Lerner, R. A. (2015)
Selection of multiple agonist antibodies from intracellular combinatorial
libraries reveals that cellular receptors are functionally pleiotropic. Curr.
Opin. Chem. Biol. 26, 1−7.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b00717
ACS Chem. Biol. 2016, 11, 2962−2980
2980
